• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

以康替唑胺附加方案成功治疗合并急性血小板减少症的重症结核病患者：一例报告

Successful Treatment of Severe Tuberculosis With Contezolid Add-On Regimen in a Patient Complicated With Acute Thrombocytopenia: A Case Report.

作者信息

Zhou Liuqing, Wang Yimin, Zhou Jixue

机构信息

Department of Pulmonary Diseases Shanghai Donghai Senior Nursing Hospital Shanghai China.

Department of Tuberculosis, 905th Hospital of PLA Navy Naval Medical University Shanghai China.

出版信息

Clin Case Rep. 2024 Dec 18;12(12):e70001. doi: 10.1002/ccr3.70001. eCollection 2024 Dec.

DOI:10.1002/ccr3.70001
PMID:39703242
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11655174/
Abstract

Polypharmacy in managing severe tuberculosis patients usually poses a risk of adverse drug reactions. Contezolid is a new oxazolidinone antibiotic showing good in vitro and in vivo activity against . Contezolid add-on regimen shows promising efficacy and safety results in managing severe tuberculosis patients complicated with acute thrombocytopenia.

摘要

在管理重症结核病患者时，联合用药通常会带来药物不良反应的风险。康替唑胺是一种新型恶唑烷酮类抗生素，在体外和体内对……均显示出良好的活性。在管理合并急性血小板减少症的重症结核病患者时，康替唑胺附加方案显示出有前景的疗效和安全性结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/953d5152f752/CCR3-12-e70001-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/fd0e61599f2f/CCR3-12-e70001-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/883f70dfaa5e/CCR3-12-e70001-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/953d5152f752/CCR3-12-e70001-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/fd0e61599f2f/CCR3-12-e70001-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/883f70dfaa5e/CCR3-12-e70001-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13bc/11655174/953d5152f752/CCR3-12-e70001-g003.jpg

相似文献

1
Successful Treatment of Severe Tuberculosis With Contezolid Add-On Regimen in a Patient Complicated With Acute Thrombocytopenia: A Case Report.以康替唑胺附加方案成功治疗合并急性血小板减少症的重症结核病患者：一例报告
Clin Case Rep. 2024 Dec 18;12(12):e70001. doi: 10.1002/ccr3.70001. eCollection 2024 Dec.
2
Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review.使用康替唑胺治疗的特殊临床情况的结核病患者：三例病例报告及文献综述
Front Med (Lausanne). 2023 Dec 14;10:1265923. doi: 10.3389/fmed.2023.1265923. eCollection 2023.
3
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.康替唑胺，一种新型恶唑烷酮类抗生素，在临床抗菌治疗中可能改善药物相关性血小板减少症。
Front Pharmacol. 2023 Apr 24;14:1157437. doi: 10.3389/fphar.2023.1157437. eCollection 2023.
4
Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients.含康替唑胺方案在25例对利奈唑胺不耐受的结核病患者中的临床应用
Infect Drug Resist. 2023 Sep 19;16:6237-6245. doi: 10.2147/IDR.S425743. eCollection 2023.
5
Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review.异基因造血干细胞移植受者罕见结核病成功治疗的报告——一个典型病例及文献复习。
Front Cell Infect Microbiol. 2023 Oct 16;13:1258561. doi: 10.3389/fcimb.2023.1258561. eCollection 2023.
6
Plasma Concentrations of Contezolid and Its Efficacy and Safety in Elderly Patients with Multidrug-Resistant Tuberculosis and Renal Insufficiency.康替唑胺在耐多药结核病合并肾功能不全老年患者中的血药浓度及其疗效和安全性
Infect Drug Resist. 2024 Jul 15;17:3047-3056. doi: 10.2147/IDR.S468543. eCollection 2024.
7
Drug Degradation Caused by Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.突变导致药物降解使结核分枝杆菌对康替唑（MRX-I）产生耐药性。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0103422. doi: 10.1128/aac.01034-22. Epub 2022 Oct 3.
8
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.康奈唑胺可在新型联合方案中替代利奈唑胺，与贝达喹啉和德拉马尼联合用于结核分枝杆菌感染的小鼠模型。
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0078923. doi: 10.1128/aac.00789-23. Epub 2023 Nov 15.
9
activities of contezolid (MRX-I) against drug-sensitive and drug-resistant .康替唑胺（MRX-I）对药敏和耐药菌的活性
Microbiol Spectr. 2023 Sep 21;11(5):e0462722. doi: 10.1128/spectrum.04627-22.
10
Successful Treatment of Intractable Tuberculous Peritonitis in a Woman with Chronic Kidney Allograft Dysfunction Using Contezolid Containing Regimen.使用含康替唑胺方案成功治疗一名患有慢性肾移植功能障碍女性的顽固性结核性腹膜炎
Infect Drug Resist. 2024 Jul 1;17:2713-2718. doi: 10.2147/IDR.S465350. eCollection 2024.

本文引用的文献

1
Novel oxazolidinones harbor potent activity against the clinical isolates of multidrug-resistant in China.新型恶唑烷酮类化合物对中国多药耐药临床分离株具有强大活性。
Front Med (Lausanne). 2022 Nov 29;9:1067516. doi: 10.3389/fmed.2022.1067516. eCollection 2022.
2
Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker.康替唑胺在一名植入无导线起搏器患者中用于治疗结核性胸膜炎的同情用药
Infect Drug Resist. 2022 Aug 12;15:4467-4470. doi: 10.2147/IDR.S373082. eCollection 2022.
3
Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
康奈唑胺（MRX-I）治疗耐多药结核病和广泛耐药结核病的前景。
Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12.
4
Contezolid: First Approval.康替唑胺：首次批准。
Drugs. 2021 Sep;81(13):1587-1591. doi: 10.1007/s40265-021-01576-0.
5
and Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis.并评价康替唑胺（MRX-I）对结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00493-18. Print 2018 Aug.
6
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.新型强效抗菌恶唑烷酮类药物（MRX-I），具有改善的类安全性特征。
J Med Chem. 2014 Jun 12;57(11):4487-97. doi: 10.1021/jm401931e. Epub 2014 Apr 16.